IN THE UNITED STATES PATENT AND TRADEMARK OFFICI

Applicants:

Ashok Tehim et al.

Continuation of:

Filed:

Application No.:

09/592,015 June 12, 2000 Group Art Unit: 1614 Examiner: Not assigned

Title:

under 37 CFR 1.97(i):

(Filed after payment of issue fee)

NEUROTROPHIN ANTAGONIST COMPOSITIONS

INFORMATION DISCLOSURE STATEMENT


Assistant Commissioner for Patents Washington, D.C. 20231 Sir: This Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection) [X] under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination). [] under 37 CFR 1.97(c) together with either: a Statement under 37 CFR 1.97(e), as checked below, or a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) [] under 37 CFR 1.97(d) together with: [] a Statement under 37 CFR 1.97(e), as checked below, and a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

		-2-			
Statem	ent Un	der 37 CFR 1.97(e)			
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or				
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
Statem	ent Un	der 37 CFR 1.704(d) (Patent Term Adjustment)			
]	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.				
[X]	Enclosed herewith is form PTO-1449:				
	[]	Copies of the cited references are enclosed.			
	[X] Copies of cited references AJ, AV-AZ and AR2-AZ2 are enclosed except those entered prior application, U.S. Application No. 09/592,015, to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]				
	[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.			
Concis	se Expla	anation Requirement (non-English references):			
The "concise explanation" requirement for reference(s) [] u satisfied by:		concise explanation" requirement for reference(s) [] under 37 CFR 1.98(a)(3) is ed by:			
	[]	the explanation provided on the attached sheet.			
	[]	the explanation provided in the Specification.			
	[]	submission of the enclosed International Search Report.			
	[]	the enclosed English language abstract.			
]	Applicant requests that the following pending applications be considered:				
xaminer's Initials					
		U.S. Patent Application No. [], Publication No. [], Publication Date [], by [inventor(s)], filed [], Docket No.: []			
		U.S. Patent Application No. [], Publication No. [], Publication Date [], by [inventor(s)], filed [], Docket No.: []			

in

U.S. Patent Application No. [], Publication No. [by [inventor(s)], filed [], Docket No.: []], Publication Date [], Examiner Date



The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

iviculou of payment	Method	of	paym	ent
---------------------	--------	----	------	-----

[]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.				
[]	Please charge Deposit Account 08-0380 in the amount of \$[enclosed.]. A copy of this Statement is			
[X]	Please charge any deficiency in fees and credit any overpaymen	nt to Deposit Account 08-0380.			

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

olyn S. Elmore

Registration No.: 37,567 Telephone: (781) 861-6240 Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: